Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections
- Neurocrine begins Phase 1 clinical study of NBI-1140675
- Positive Market Outlook for Neurocrine’s Crenessity Driven by Unmet Needs and Strong Physician Adoption
- Neurocrine reports patient-reported outcome data from KINECT-PRO study
- Neurocrine price target lowered to $183 from $191 at JPMorgan